OBJECTIVE: Conventional chemotherapy and radiotherapy produce marginal survival benefits in pancreatic cancer, underscoring the need for novel therapies. The aim of this study is to develop an adoptive T cell transfer approach to target tumours expressing prostate stem cell antigen (PSCA), a tumour-associated antigen that is frequently expressed by pancreatic cancer cells. METHODS: Expression of PSCA on cell lines and primary tumour samples was confirmed by immunohistochemistry. Healthy donor- and patient-derived T cells were isolated, activated in vitro using CD3/CD28, and transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) targeting PSCA. The ability of these cells to kill tumour cells was analysed by chromium-51 (Cr(51)) release. RESULTS: Prostate stem cell antigen was expressed on >70% of the primary tumour samples screened. Activated, CAR-modified T cells could be readily generated in clinically relevant numbers and were specifically able to kill PSCA-expressing pancreatic cancer cell lines with no non-specific killing of PSCA-negative target cells, thus indicating the potential efficacy and safety of this approach. CONCLUSIONS: Prostate stem cell antigen is frequently expressed on pancreatic cancer cells and can be targeted for immune-mediated destruction using CAR-modified, adoptively transferred T cells. The safety and efficacy of this approach indicate that it deserves further study and may represent a promising novel treatment for patients with pancreatic cancer.
OBJECTIVE: Conventional chemotherapy and radiotherapy produce marginal survival benefits in pancreatic cancer, underscoring the need for novel therapies. The aim of this study is to develop an adoptive T cell transfer approach to target tumours expressing prostate stem cell antigen (PSCA), a tumour-associated antigen that is frequently expressed by pancreatic cancer cells. METHODS: Expression of PSCA on cell lines and primary tumour samples was confirmed by immunohistochemistry. Healthy donor- and patient-derived T cells were isolated, activated in vitro using CD3/CD28, and transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) targeting PSCA. The ability of these cells to kill tumour cells was analysed by chromium-51 (Cr(51)) release. RESULTS: Prostate stem cell antigen was expressed on >70% of the primary tumour samples screened. Activated, CAR-modified T cells could be readily generated in clinically relevant numbers and were specifically able to kill PSCA-expressing pancreatic cancer cell lines with no non-specific killing of PSCA-negative target cells, thus indicating the potential efficacy and safety of this approach. CONCLUSIONS: Prostate stem cell antigen is frequently expressed on pancreatic cancer cells and can be targeted for immune-mediated destruction using CAR-modified, adoptively transferred T cells. The safety and efficacy of this approach indicate that it deserves further study and may represent a promising novel treatment for patients with pancreatic cancer.
Authors: Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg Journal: Science Date: 2006-08-31 Impact factor: 47.728
Authors: Cor H J Lamers; Stefan Sleijfer; Arnold G Vulto; Wim H J Kruit; Mike Kliffen; Reno Debets; Jan W Gratama; Gerrit Stoter; Egbert Oosterwijk Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: M E Dudley; J Wunderlich; M I Nishimura; D Yu; J C Yang; S L Topalian; D J Schwartzentruber; P Hwu; F M Marincola; R Sherry; S F Leitman; S A Rosenberg Journal: J Immunother Date: 2001 Jul-Aug Impact factor: 4.456
Authors: Moritz N Wente; Anjali Jain; Evelyn Kono; Pascal O Berberat; Thomas Giese; Howard A Reber; Helmut Friess; Markus W Büchler; Robert E Reiter; Oscar J Hines Journal: Pancreas Date: 2005-08 Impact factor: 3.327
Authors: Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg Journal: Science Date: 2002-09-19 Impact factor: 47.728
Authors: Ann M Leen; Uluhan Sili; Elio F Vanin; Alan M Jewell; Weidong Xie; Dario Vignali; Pedro A Piedra; Malcolm K Brenner; Cliona M Rooney Journal: Blood Date: 2004-07-20 Impact factor: 22.113
Authors: Elham Pishali Bejestani; Marc Cartellieri; Ralf Bergmann; Armin Ehninger; Simon Loff; Michael Kramer; Johannes Spehr; Antje Dietrich; Anja Feldmann; Susann Albert; Martin Wermke; Michael Baumann; Mechthild Krause; Martin Bornhäuser; Gerhard Ehninger; Michael Bachmann; Malte von Bonin Journal: Oncoimmunology Date: 2017-06-20 Impact factor: 8.110
Authors: Aaron E Foster; Aruna Mahendravada; Nicholas P Shinners; Wei-Chun Chang; Jeannette Crisostomo; An Lu; Mariam Khalil; Eva Morschl; Joanne L Shaw; Sunandan Saha; MyLinh T Duong; Matthew R Collinson-Pautz; David L Torres; Tania Rodriguez; Tsvetelina Pentcheva-Hoang; J Henri Bayle; Kevin M Slawin; David M Spencer Journal: Mol Ther Date: 2017-07-08 Impact factor: 11.454
Authors: Usanarat Anurathapan; Robert C Chan; Hakeem F Hindi; Roopa Mucharla; Pradip Bajgain; Brendan C Hayes; William E Fisher; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Ann M Leen; Juan F Vera Journal: Mol Ther Date: 2013-11-28 Impact factor: 11.454
Authors: B M Wolpin; E M O'Reilly; Y J Ko; L S Blaszkowsky; M Rarick; C M Rocha-Lima; P Ritch; E Chan; J Spratlin; T Macarulla; E McWhirter; D Pezet; M Lichinitser; L Roman; A Hartford; K Morrison; L Jackson; M Vincent; L Reyno; M Hidalgo Journal: Ann Oncol Date: 2013-02-28 Impact factor: 32.976
Authors: Sunitha Kakarla; Kevin K H Chow; Melinda Mata; Donald R Shaffer; Xiao-Tong Song; Meng-Fen Wu; Hao Liu; Lisa L Wang; David R Rowley; Klaus Pfizenmaier; Stephen Gottschalk Journal: Mol Ther Date: 2013-06-04 Impact factor: 11.454
Authors: Kirstin A Zettlitz; Wen-Ting K Tsai; Scott M Knowles; Naoko Kobayashi; Timothy R Donahue; Robert E Reiter; Anna M Wu Journal: J Nucl Med Date: 2018-03-30 Impact factor: 10.057